Literature DB >> 31957642

Cataplexy and ataxia: red flags for the diagnosis of DNA methyltransferase 1 mutation.

Emanuela Postiglione1, Elena Antelmi1,2, Fabio Pizza1,2, Stefano Vandi1,2, Chiara La Morgia1,2, Valerio Carelli1,2, Stefania Nassetti2, Marco Seri3, Giuseppe Plazzi1.   

Abstract

None: Mutations in exons 21 and 20 of the DMNT1 gene have been associated with two multisystem neurodegenerative diseases that involve central and peripheral nervous system ADCADN (Autosomal Dominant Cerebellar Ataxia with Deafness and Narcolepsy) and HSAN 1E (Hereditary Sensory and Autonomic Neuropathy IE). We describe a new case of ADCADN that was referred to us in the suspicion of secondary narcolepsy. A 44-year-old female with personal and familiar longstanding history of progressive bilateral sensorineural deafness, and sensitive cerebellar ataxia, presenting with brief episodes of falls while laughing and excessive diurnal somnolence. Clinical and neurophysiological evaluations reveled signs of cerebellar, pyramidal, peripheral, cognitive involvement, and optical atrophy. A 48-hour continuous polysomnography (PSG) and Multiple Sleep Latency Test at first evaluation revealed a normal sleep structure with frequent diurnal sleep episodes and a pathological sleep latency without sleep onset REM periods (SOREMPs). Normal level of cerebrospinal fluid (CSF) hypocretine 1 was detected. Given the reminiscence with DNMT 1 spectrum a direct sequencing of exons 20 and 21 of the DNMT1 gene was performed revealing the p.Glu575Lys mutation in exon 21 in the proband and her mother. During the 4 years of follow-up her walking ability declined, she became more somnolent and repeated PSG documented REM sleep latency shortening, and finally the evidence of de novo spontaneous SOREMPs, although normal CSF hrct-1 at second revaluation. This case highlights the progressive course of disease although a full-blown picture of classical narcolepsy type 1 was never reached.
© 2020 American Academy of Sleep Medicine.

Entities:  

Keywords:  DNMT1 mutation; ataxia; cataplexy; narcolepsy; secondary narcolepsy

Mesh:

Substances:

Year:  2019        PMID: 31957642      PMCID: PMC7052993          DOI: 10.5664/jcsm.8140

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  9 in total

Review 1.  Cataplexy and Its Mimics: Clinical Recognition and Management.

Authors:  Sigrid Pillen; Fabio Pizza; Karlien Dhondt; Thomas E Scammell; Sebastiaan Overeem
Journal:  Curr Treat Options Neurol       Date:  2017-06       Impact factor: 3.598

2.  Autosomal dominant cerebellar ataxia deafness and narcolepsy.

Authors:  A Melberg; J Hetta; N Dahl; I Nennesmo; M Bengtsson; R Wibom; C Grant; K H Gustavson; P O Lundberg
Journal:  J Neurol Sci       Date:  1995-12       Impact factor: 3.181

Review 3.  Cataplexy and sleep disorders in Niemann-Pick type C disease.

Authors:  Sona Nevsimalova; Vera Malinova
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

4.  A novel de novo exon 21 DNMT1 mutation causes cerebellar ataxia, deafness, and narcolepsy in a Brazilian patient.

Authors:  José Luiz Pedroso; Orlando Graziani Povoas Barsottini; Ling Lin; Atle Melberg; Acary S B Oliveira; Emmanuel Mignot
Journal:  Sleep       Date:  2013-08-01       Impact factor: 5.849

5.  Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy.

Authors:  Juliane Winkelmann; Ling Lin; Barbara Schormair; Birgitte R Kornum; Juliette Faraco; Giuseppe Plazzi; Atle Melberg; Ferdinando Cornelio; Alexander E Urban; Fabio Pizza; Francesca Poli; Fabian Grubert; Thomas Wieland; Elisabeth Graf; Joachim Hallmayer; Tim M Strom; Emmanuel Mignot
Journal:  Hum Mol Genet       Date:  2012-02-09       Impact factor: 6.150

6.  Novel mutation in the replication focus targeting sequence domain of DNMT1 causes hereditary sensory and autonomic neuropathy IE.

Authors:  Junhui Yuan; Yujiro Higuchi; Tatsui Nagado; Satoshi Nozuma; Tomonori Nakamura; Eiji Matsuura; Akihiro Hashiguchi; Yusuke Sakiyama; Akiko Yoshimura; Hiroshi Takashima
Journal:  J Peripher Nerv Syst       Date:  2013-03       Impact factor: 3.494

7.  Narcolepsy is a common phenotype in HSAN IE and ADCA-DN.

Authors:  Keivan Kaveh Moghadam; Fabio Pizza; Chiara La Morgia; Christian Franceschini; Caterina Tonon; Raffaele Lodi; Piero Barboni; Marco Seri; Simona Ferrari; Rocco Liguori; Vincenzo Donadio; Piero Parchi; Ferdinando Cornelio; Domenico Inzitari; Andrea Mignarri; Giuseppe Capocchi; Maria Teresa Dotti; Juliane Winkelmann; Ling Lin; Emmanuel Mignot; Valerio Carelli; Giuseppe Plazzi
Journal:  Brain       Date:  2014-04-10       Impact factor: 13.501

8.  Defects of mutant DNMT1 are linked to a spectrum of neurological disorders.

Authors:  Jonathan Baets; Xiaohui Duan; Yanhong Wu; Gordon Smith; William W Seeley; Inès Mademan; Nicole M McGrath; Noah C Beadell; Julie Khoury; Maria-Victoria Botuyan; Georges Mer; Gregory A Worrell; Kaori Hojo; Jessica DeLeon; Matilde Laura; Yo-Tsen Liu; Jan Senderek; Joachim Weis; Peter Van den Bergh; Shana L Merrill; Mary M Reilly; Henry Houlden; Murray Grossman; Steven S Scherer; Peter De Jonghe; Peter J Dyck; Christopher J Klein
Journal:  Brain       Date:  2015-02-11       Impact factor: 13.501

9.  Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss.

Authors:  Christopher J Klein; Maria-Victoria Botuyan; Yanhong Wu; Christopher J Ward; Garth A Nicholson; Simon Hammans; Kaori Hojo; Hiromitch Yamanishi; Adam R Karpf; Douglas C Wallace; Mariella Simon; Cecilie Lander; Lisa A Boardman; Julie M Cunningham; Glenn E Smith; William J Litchy; Benjamin Boes; Elizabeth J Atkinson; Sumit Middha; P James B Dyck; Joseph E Parisi; Georges Mer; David I Smith; Peter J Dyck
Journal:  Nat Genet       Date:  2011-05-01       Impact factor: 38.330

  9 in total
  1 in total

Review 1.  Sleep, cerebrospinal fluid, and the glymphatic system: A systematic review.

Authors:  Pearlynne L H Chong; Dea Garic; Mark D Shen; Iben Lundgaard; Amy J Schwichtenberg
Journal:  Sleep Med Rev       Date:  2021-11-18       Impact factor: 11.609

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.